MediXall Appoints Dr. Pedro A. Sanchez, D.O., to be its First Medical Director

MediXall Group, Inc. Now Trading on OTCQB Under Symbol MDXL
February 3, 2017
MediXall Group, Inc. Announces Formation of an Advisory Board and Its First Appointment
February 3, 2017

FT. LAUDERDALE, FL– MediXall Group, Inc. ( OTCQB : MDXL ) is pleased to announce the appointment of its first Medical Director, Dr. Pedro A. Sanchez, D.O. Dr. Sanchez is a graduate of Southeastern College of Osteopathic Medicine in Ft. Lauderdale, Florida, and served his residency at Wellington Regional Medical Center in Wellington, Florida. Dr. Sanchez is Board Certified by the American Osteopathic Board of Family Physicians, and has been a successful family practice physician for over 25 years.
Carl L. Larsen, President of MediXall Group, Inc. commented, “We are extremely pleased to have Dr. Sanchez join our team officially. We anticipate that Dr. Sanchez will have a very positive impact on our operation from providing Subject Matter Expertise to assisting in the analysis and review of future acquisitions. Dr. Sanchez’ broad grasp of so many facets of the medical and healthcare industry, including his deep clinical and practice management experience, will greatly benefit the development and deployment of the key portfolio companies that we are building and looking to acquire.”
Dr. Sanchez commented, “MediXall is truly an innovative step forward in the creation of a critical mass for healthcare information and technology. The MediXaid e-Marketplace Platform is the perfect starting point and will benefit both healthcare providers and the consumer with greater transparency and competition, both very much needed in healthcare today. The MediXaid platform concept is amazing in the way it will provide greater information and connect the patient with the latest information technology empowering them to better manage their own wellness. I believe MediXaid will be a true disruptor in the healthcare industry and will lead the way to a major shift in healthcare cost containment and reduction.”
Mr. Larsen noted that Dr. Sanchez “will have a continuing input in key areas as we continue to build and deploy the MediXaid e-Marketplace, and going forward as we add additional companies to our portfolio. Our goal, as a team, is to continue to improve healthcare quality, improve transparency and create efficiencies reducing cost by building a more responsive and easier to use platform.”
The Company has also recently announced recently that it has just completed the transition of the MediXall Group, Inc. into a public corporation trading as MDXL (OTCQB).
About The MediXall Group, Inc.
The MediXall Group, Inc. (MediXall) is implementing a new model for a healthcare “incubator” hub to enable healthcare and providers and consumers to find a best match for their healthcare related needs and associated products. MediXall Incubator will seek to acquire, or partner with owners of superior healthcare inventions and create mutually beneficial agreements that will generate revenue through the licensing of patented intellectual property.
For more information, please visit About MediXaid™
MediXaid represents the concept for a regional medical/healthcare e-marketplace that will allow patients to confidentially (using coded profiles and encrypted member identification) solicit for medical and healthcare services, such as a diagnostic procedure (MRI) within a given radius of their location. It is intended to have multiple Providers for all services, reverse bidding for the product or services under a variety of conditions that may be selected by the patients such as location/proximity, delivery time and insurance network affiliation to be bid on by the Provider based on their cost structure, immediate capacity and availability and ability to meet the Patient’s selections.
Safe Harbor Statement
Certain statements contained in this news release that are not based on historical facts are forward‐looking statements, as the term is defined in the Private Securities Litigation Reform Act of 1995, and are subject to substantial risks and uncertainties. These risks and uncertainties are in part detailed on Form 10‐K for the fiscal year ended December 31, 2016, and its Quarterly Report on Form 10‐Q (“Quarterly Reports”) which was filed with the Securities and Exchange Commission. Forward‐looking statements can be identified by the use of words such as “expects,” “plans,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates” and “could,” other words of similar meaning and the negative form of such words. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by these forward‐looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to obtain the clearance it seeks from FINRA for the quotation of its securities on the OTCBB, the continued market liquidity of its securities after they are delisted from Amex, the ability of the Company to properly execute its business model, to raise substantial and immediate additional capital in the current credit markets, to implement its business model, to continue its upward revenue growth trend through the end of the current fiscal year and into fiscal 2017, to control patient medical costs relative to income received, to attract and retain qualified executive, management and operational personnel, to continue growing its patient base, to negotiate or renegotiate favorable terms for its current debt and future financings, to negotiate favorable agreements with a diversified provider and to supply the services required by consumers and provider clients. There can also be no assurance that the deployment by the Company of its MediXaid technology platform will be commercially successful or that the continuing infrastructure development, hosting, security, sales and servicing will be accomplished in a timely manner or at all or be accepted by clients. The MediXaid platform may also experience further potential complications during utilization by clients, technical and software setbacks and any unexpected costs of development, as well as pricing and completive pressures, and the capital necessary to deploy it may not be available on time or at all. The Company is also subject to changes in federal and state government regulations dealing with its provider system and technology solutions that could have a material adverse effect on its financial condition and result in interruptions of services, and to contractual risk, expenses and compliance with its alliance partner(s) agreements. The Company does not undertake any obligation to release any revisions to these forward‐looking statements publicly to reflect events occurring after the date of this report or to reflect the occurrence of unanticipated events. As a result, investors should not place undue reliance on these forward‐looking statements.

Leave a Reply